Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Landiolol hydrochloride for prevention of postoperative atrial fibrillation after esophageal cancer surgery: The double-blind, randomized, placebo-controlled trial

Trial Profile

Landiolol hydrochloride for prevention of postoperative atrial fibrillation after esophageal cancer surgery: The double-blind, randomized, placebo-controlled trial

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 01 Jul 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Landiolol (Primary)
  • Indications Atrial fibrillation
  • Focus Therapeutic Use
  • Acronyms APPLE
  • Most Recent Events

    • 01 Jul 2017 Primary endpoint (Incidence of atrial fibrillation ) has been met, as per the results published in the British Journal of Surgery.
    • 01 Jul 2017 Results published in the British Journal of Surgery
    • 01 Jul 2017 Status changed from active, no longer recruiting to completed, as per results published in the British Journal of Surgery.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top